Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. It works by stimulating the GLP-1 receptors in the pancreas, leading to increased insulin secretion and decreased glucagon release. This helps lower blood sugar levels and promotes weight loss. Liraglutide is administered as a once-daily injection.
| Aliase | liraglutide |
| CAS | 204656-20-2 |
| EINECS | 1592732-453-0 |
| MOLECULAR FORMULA | C172H265N43O51 |
| MOLECULAR WEIGHT | 3751.20000 |
Our Service Advantages
Packaging and Delivery
The company fully supports customized packing and shipping preferences to meet specific needs, ensuring top priority for customer requirements.
Supply Ability
The MOQ varies by product due to their unique specifications. We encourage you to reach out for detailed information tailored to the specific product of interest.
Lead Time
Delivery schedules adapt to seasonal demands, with a 15 working day delivery time during peak seasons and 7 to 13 working days in off-peak seasons, showcasing efficient and timely delivery.
Liraglutide Research
MEDICAL USES
Liraglutide helps to induce and sustain weight loss in patients with obesity. Its efficacy is comparable to other available agents but it offers the unique benefit of improved glycemic control. Additional studies are needed to determine its long term efficacy and safety profile.
Liraglutide AND WEIGHT LOSS
Liraglutide, a Glucagon-like Peptide-1 (GLP-1) receptor agonist, has been used in the United States since 2010 for the treatment of type 2 diabetes in doses of 1.2mg and 1.8mg, while the dose for obesity needs to be increased to 3.0mg. It should be noted that this drug should not be used with other GLP-1 drugs, and should be discontinued if patients do not lose 4% of their original body weight after 16 weeks of use. Suitable for patients with a combination of a low-calorie diet and exercise, a body mass index (BMI) greater than 30, or a BMI greater than 27, but with obesity-related complications such as diabetes, hypertension, or hyperlipidemia.
FAQ
1.Manufacturer or trading company? Where is the company located?
We pride ourselves on being an integrated industry and trade company, nestled in the heart of Zhengzhou, Henan Province.
2.Where are the main markets?
Our global footprint extends across Europe, America, Southeast Asia, the Middle East, and Africa. We are committed to delivering high-quality products and services to every corner of the world, ensuring our presence is felt internationally.
3.Can you provide a product catalog?
Yes, we can! Please contact our sales manager directly. We will promptly send you our detailed product catalog and pricing information to suit your needs.
4.About the terms and conditions of payment.
We offer a variety of payment options to accommodate your convenience, including T/T (Telegraphic Transfer), Western Union, MoneyGram, and cryptocurrency options, ensuring a seamless transaction process.
About US
Nestled in the heart of Henan Province, Zhengzhou Plastic Body Peptide Trading Co., Ltd embarked on its journey to redefine the chemical and pharmaceutical landscape. Founded on the principles of innovation, integrity, and excellence, we've dedicated ourselves to producing top-tier local anesthetics, pharmaceutical intermediates, steroids, and other crucial raw materials.
Driven by a passion for progress and a commitment to quality, our team has bridged continents, connecting with partners in North America, Eastern Europe, Southeast Asia, and beyond. Each product and solution we develop carries the mark of our rigorous research and customer-centric approach, aiming not just to meet but exceed global standards.
References
1.Liraglutide for type 2 diabetes. Med Lett Drugs Ther. 2022 Jul 11;64(1654):105-107. [PubMed]
2.Collins L, Costello RA. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Jan 13, 2023. Glucagon-like Peptide-1 Receptor Agonists. [PubMed]
3.Dahl D, Onishi Y, Norwood P, Huh R, Bray R, Patel H, Rodríguez Á. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. JAMA. 2022 Feb 08;327(6):534-545. [PMC free article] [PubMed]
4.LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. National Institute of Diabetes and Digestive and Kidney Diseases; Bethesda (MD): Jun 20, 2022. Tirzepatide. [PubMed]
5.Valenzuela-Vallejo L, Guatibonza-García V, Mantzoros CS. Recent guidelines for Non-Alcoholic Fatty Liver Disease (NAFLD)/ Fatty Liver Disease (FLD): Are they already outdated and in need of supplementation? Metabolism. 2022 Nov;136:155248. [PubMed]
6.Sun B, Willard FS, Feng D, Alsina-Fernandez J, Chen Q, Vieth M, Ho JD, Showalter AD, Stutsman C, Ding L, Suter TM, Dunbar JD, Carpenter JW, Mohammed FA, Aihara E, Brown RA, Bueno AB, Emmerson PJ, Moyers JS, Kobilka TS, Coghlan MP, Kobilka BK, Sloop KW. Structural determinants of dual incretin receptor agonism by tirzepatide. Proc Natl Acad Sci USA. 2022 Mar 29;119(13):e2116506119. [PMC free article] [PubMed]
7. Bucheit J, Ayers J, Pamulapati L, Browning A, Sisson E. A Novel Dual Incretin Agent, Tirzepatide (LY3298176), for the Treatment of Type 2 Diabetes Mellitus and Cardiometabolic Health. J Cardiovasc Pharmacol. 2022 Aug 01;80(2):171-179. [PubMed]
8. Drugs and Lactation Database (LactMed®) [Internet]. National Institute of Child Health and Human Development; Bethesda (MD): Jun 20, 2022. Tirzepatide. [PubMed]
9.Farzam K, Jan A. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Dec 27, 2022. Beta Blockers. [PubMed]
10. Trujillo J. Safety and tolerability of once-weekly GLP-1 receptor agonists in type 2 diabetes. J Clin Pharm Ther. 2020 Sep;45 Suppl 1(Suppl 1):43-60. [PMC free article] [PubMed]
